Not applicableWithdrawnNCT02526719What this trial is testingNipple Delay Prior to Nipple Sparing Mastectomy: A Pilot RCTWho this might be right forBreast Cancer University Health Network, Toronto
Testing effectiveness (Phase 2)Ended earlyNCT00589238What this trial is testingPaclitaxel, Doxorubicin, and Cyclophosphamide With Or Without Carboplatin in Treating Women With Locally Advanced Breast Cancer That Can Be Removed by SurgeryWho this might be right forBreast Cancer National Cancer Centre, Singapore 16
Testing effectiveness (Phase 2)Looking for participantsNCT05485766What this trial is testingNovel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast CancerWho this might be right forTriple Negative Breast NeoplasmsTriple Negative Breast CancerBreast Neoplasms+5 more Okayama University 23
Testing effectiveness (Phase 2)Study completedNCT00628251What this trial is testingDose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian CancerWho this might be right forOvarian Neoplasms AstraZeneca 97
Testing effectiveness (Phase 2)Study completedNCT00494442What this trial is testingStudy to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian CancerWho this might be right forOvarian Neoplasm AstraZeneca 58
Testing effectiveness (Phase 2)Study completedNCT00494234What this trial is testingStudy to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast CancerWho this might be right forBreast Neoplasms AstraZeneca 54
Early research (Phase 1)Study completedNCT00516373What this trial is testingAssess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)Who this might be right forOvarian NeoplasmsBRCA1 ProteinBRCA2 Protein AstraZeneca 98
Early research (Phase 1)UnknownNCT01022333What this trial is testingThe Potential for Oral Diindolylmethane (DIM) Supplementation to Increase the Production of the BRCA1 Protein in BRCA1 Mutation CarriersWho this might be right forBreast Cancer Women's College Hospital 300
Testing effectiveness (Phase 2)Ended earlyNCT01990352What this trial is testingCorrelate BRCA1 Protein Expression With Response to DNA Damaging ChemotherapyWho this might be right forBreast Cancer University of Arizona 24
Early research (Phase 1)Study completedNCT05904730What this trial is testingPhase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 MutationsWho this might be right forBreast CancerOvarian CancerBreast Neoplasms+5 more Lynkcell Europe 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439227What this trial is testingTesting AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)Who this might be right forAdvanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more National Cancer Institute (NCI) 35
Early research (Phase 1)Study completedNCT01286987What this trial is testingStudy of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid TumorsWho this might be right forAdvanced or Recurrent Solid TumorsBreast NeoplasmsOvarian Cancer, Epithelial+4 more Pfizer 113
Not applicableUnknownNCT02959398What this trial is testingEvaluation of Tomosynthesis for Characterization and the Management of Breast LesionsWho this might be right forBreast NeoplasmsTomosynthesisBRCA1 Protein+1 more Assistance Publique - Hôpitaux de Paris 2,000